Related Experiment Videos
Prostaglandin E1 therapy for impotence, comparison with papaverine
C M Earle1, E J Keogh, Z S Wisniewski
1Reproductive Medicine Research Institute, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia.
The Journal of Urology
|January 1, 1990
Summary
Prostaglandin E1 demonstrated superior efficacy over papaverine for treating erectile dysfunction, with more patients preferring and achieving full erections with prostaglandin E1.
Area of Science:
- Urology
- Pharmacology
Background:
- Erectile dysfunction (ED) is a common condition affecting many men.
- Pharmacological treatments are a cornerstone of ED management.
Purpose of the Study:
- To compare the efficacy of prostaglandin E1 (PGE1) with papaverine for treating erectile dysfunction.
- To assess patient preference between PGE1 and papaverine.
Main Methods:
- A single-blind, crossover trial involving 129 men with erectile dysfunction.
- Patients received intracavernous injections of PGE1 (5 micrograms) or papaverine (18 mg) one month apart.
Main Results:
- Prostaglandin E1 produced better erections in 55.8% of men, compared to papaverine.
- 27% of patients preferred papaverine, while 55% preferred PGE1.
- Full erections were achieved by 34 men with PGE1 versus 17 with papaverine.
Conclusions:
- Prostaglandin E1 is a more effective treatment for erectile dysfunction than papaverine.
- Patient preference and objective measures support the use of PGE1 in ED management.